Dosing chart / Weight & metabolic
Semaglutide vs Cagrilintide
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| Semaglutide | Cagrilintide | |
|---|---|---|
| Status | FDA-approved | Clinical trials |
| Also known as | Ozempic, Wegovy | part of CagriSema |
| Typical dose | 0.25 mg rising to 2.4 mg | 0.25 mg rising to 2.4 mg |
| How often | Weekly | Weekly |
| Schedule | Once weekly. Start at 0.25 mg and step up every 4 weeks: 0.5, 1, 1.7, then 2.4 mg. | Once weekly in trials, escalated every 4 weeks. |
| Daily equivalent | ≈ 36–343 mcg/day | ≈ 36–343 mcg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | Ongoing | Trials ran 68 weeks |
| Notes | Wegovy schedule shown. A 7.2 mg weekly dose (Wegovy HD) was approved in March 2026 for adults who have tolerated 2.4 mg for at least 4 weeks. Ozempic for diabetes is maintained at 0.5–2 mg weekly. Brand products are prefilled pens; the calculator applies to vials only. Boxed warning for thyroid C-cell tumors. | Long-acting amylin analog, studied mostly in combination with semaglutide. Not yet approved. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Semaglutide and Cagrilintide pages.
Advertisement